BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Earnings Results

BioCryst Pharmaceuticals (NASDAQ:BCRX) released its quarterly earnings results on Thursday. The biotechnology company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $1.05, Briefing.com reports. BioCryst Pharmaceuticals had a negative net margin of 1.46% and a negative return on equity of 4.24%. The firm had revenue of $163.28 million for the quarter, compared to analyst estimates of $151.32 million. During the same period in the previous year, the business earned ($0.13) earnings per share. The company’s revenue for the quarter was up 209.1% compared to the same quarter last year.

Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:

• BioCryst closed 2025 with strong ORLADEYO sales of $601.8M (up 38% YoY; 43% ex‑Europe) and launched ORLADEYO Pellets for ages 2–<12, which management expects to increase pediatric diagnosis and long‑term patient growth.
• Navenibart Phase 3 (Alpha Orbit) is recruiting well with ~145 patients expected by mid‑2026; Phase 2 showed ~90–92% mean attack reductions and a mean attack rate of 0.16/month, and the company is targeting a BLA submission by end‑2027 and approval in late‑2028.
• The company reported record non‑GAAP operating profit of $214M, ended 2025 with $337.5M in cash/investments and secured a $400M financing facility with Blackstone, highlighting strong liquidity and capital optionality.
• Early‑stage KLK5 inhibitor BCX‑17725 completed healthy‑volunteer dosing with favorable safety and epidermal distribution and is moving into patient cohorts (up to 12 in Part 4) with data expected by year‑end 2026, offering pipeline optionality but still early evidence.
• Management warns of a likely Q1 revenue dip due to reauthorization season and expects higher non‑GAAP R&D spend in 2026 (guidance OpEx $450–$470M) to complete navenibart Phase 3 and CMC work, which will raise near‑term operating expenses despite a goal to remain profitable.

BioCryst Pharmaceuticals Stock Performance

NASDAQ BCRX traded up $0.35 on Thursday, reaching $7.90. The company had a trading volume of 8,059,388 shares, compared to its average volume of 4,455,107. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -158.00 and a beta of 0.83. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.31. The company’s fifty day moving average is $7.10 and its 200-day moving average is $7.39.

Analyst Upgrades and Downgrades

BCRX has been the subject of a number of research analyst reports. Citizens Jmp cut their price target on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a report on Wednesday, November 5th. Royal Bank Of Canada cut their price target on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. HC Wainwright raised their price target on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 15th. Barclays dropped their price objective on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, November 4th. Finally, Zacks Research lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.64.

Insider Activity at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 21,773 shares of the company’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $7.65, for a total transaction of $166,563.45. Following the completion of the transaction, the insider directly owned 398,751 shares of the company’s stock, valued at $3,050,445.15. This represents a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 183,453 shares of company stock valued at $1,330,965 in the last 90 days. Insiders own 5.10% of the company’s stock.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. RA Capital Management L.P. acquired a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at $123,452,000. Deerfield Management Company L.P. increased its position in shares of BioCryst Pharmaceuticals by 159.4% in the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after acquiring an additional 7,477,000 shares during the last quarter. State Street Corp increased its position in shares of BioCryst Pharmaceuticals by 12.9% in the fourth quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock valued at $86,371,000 after acquiring an additional 1,265,773 shares during the last quarter. Janus Henderson Group PLC raised its holdings in BioCryst Pharmaceuticals by 7,807.2% during the fourth quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock worth $57,791,000 after acquiring an additional 7,310,745 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in BioCryst Pharmaceuticals by 22.1% during the third quarter. Arrowstreet Capital Limited Partnership now owns 5,225,986 shares of the biotechnology company’s stock valued at $39,665,000 after purchasing an additional 947,431 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals News Roundup

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Q4 earnings and revenue materially beat expectations — GAAP EPS $1.12 vs. consensus $0.07; revenue $406.6M vs. $151.3M consensus. The jump in revenue and earnings (vs. a loss a year ago) supports re-rating of the business. Read More.
• Positive Sentiment: Astria acquisition expands HAE franchise and management provided guidance tied to the deal — the strategic tuck-in strengthens ORLADEYO-related portfolio and revenue runway, supporting upside to long-term HAE sales. Read More.
• Positive Sentiment: Full-year 2025 update: ORLADEYO net revenue was $601.8M (+38% y/y; +43% excluding European divestiture) — demonstrates continued product-level growth that underpins the strong quarterly top line. Read More.
• Neutral Sentiment: Company hosted a conference call and published a slide deck with more detail on results and outlook — useful for hearing management’s assumptions on commercialization and integration of Astria. Read More.
• Neutral Sentiment: Market commentary highlights that the Astria deal and accompanying HAE data have been a focus for bulls — this is driving intraday trade flows and sentiment. Read More.
• Neutral Sentiment: Short interest data reported in the public record was anomalous/unclear (zero shares reported with NaN changes) — current data isn’t informative for a short-covering story. Read More.
• Negative Sentiment: Despite the top-line beat, profitability metrics remain mixed: the company reported a negative net margin and negative ROE, and some analysts still model a FY loss — investors should watch margin conversion and guidance assumptions. Read More.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.